Research peptides are not approved for human use in most countries including India. This page is for educational purposes only. Consult a physician before use.
What is GHRH and How Does Sermorelin Work?
Growth hormone-releasing hormone (GHRH) is a 44-amino acid hypothalamic peptide that is the primary upstream signal for growth hormone production. It is released from the arcuate nucleus of the hypothalamus in pulses, travels to the anterior pituitary, and binds GHRH receptors on somatotroph cells, triggering the synthesis and release of growth hormone (GH).
Sermorelin is a synthetic analogue of the first 29 amino acids of GHRH — the biologically active N-terminal fragment (GHRH 1-29). This truncated form retains full receptor binding affinity and signaling capacity while being smaller and more stable than the full 44-amino acid hormone.
The downstream pathway: Sermorelin injection → pituitary GHRH receptor binding → GH synthesis and release into bloodstream → liver IGF-1 production → systemic anabolic and metabolic effects. This is a physiological cascade — it works with the body's existing hardware rather than bypassing it.
Why Sermorelin is Physiologically Different from Exogenous HGH
This distinction is central to why many longevity physicians prefer sermorelin over direct HGH injections:
- Feedback loop preservation: When sermorelin stimulates GH release and IGF-1 rises, somatostatin (the GH-inhibiting hormone) increases, naturally limiting further GH release. The system self-regulates. Exogenous HGH bypasses this entirely.
- Pulsatile release: Natural GH is released in pulses — particularly a large pulse 30-60 minutes after sleep onset. Sermorelin preserves this pulsatile pattern, which is physiologically important for receptor sensitivity and downstream effects. Continuous HGH administration blunts receptor sensitivity.
- No pituitary suppression: Exogenous HGH can suppress the pituitary's own GH production over time (similar to how exogenous testosterone suppresses natural testosterone). Sermorelin, by stimulating rather than replacing the pituitary, avoids this.
- Reduced acromegaly risk: Without the feedback loop, exogenous HGH can cause supraphysiological GH and IGF-1 levels if dosed incorrectly. Sermorelin's self-limiting mechanism makes this much less likely.
- Lower cost and complexity: Sermorelin is significantly less expensive than pharmaceutical HGH and typically more accessible in the research peptide market.
The IGF-1 Tracking Rationale
GH itself is difficult to measure accurately because of its pulsatile nature — a single blood draw may catch a high or low point in the pulse. IGF-1 (insulin-like growth factor 1), produced by the liver in response to GH, is the better clinical proxy because it has a longer half-life and reflects average GH activity over days to weeks.
Protocol for IGF-1 monitoring:
- Baseline measurement: Test IGF-1 before starting sermorelin. In men over 40, IGF-1 is often in the low-normal range or below — this establishes the starting point.
- Target range: Most practitioners target the upper third of the age-adjusted reference range, not supraphysiological levels. This represents physiological optimization, not excess.
- Recheck timing: Test again at 8-12 weeks. IGF-1 responds over weeks to months of GH stimulation, not days.
- Dose adjustment: If IGF-1 hasn't moved meaningfully, the dose may need to be increased, the timing adjusted, or the combination with a GHRP (like ipamorelin) considered.
FDA Approval History
Sermorelin (as Geref) was approved by the FDA for the treatment of idiopathic growth hormone deficiency in children. It was later withdrawn from the US market not due to safety concerns but for commercial reasons — pharmaceutical economics made the more profitable direct HGH products preferable to the manufacturer. This approval history gives sermorelin a stronger human safety precedent than most research peptides, which have never been approved anywhere.
Dosing Protocol
The most widely used protocol for longevity and body composition optimization:
- Dose: 0.2-0.3mg (200-300mcg) subcutaneous injection
- Timing: 30-60 minutes before sleep, on an empty stomach (food — especially carbohydrates — blunts GH release)
- Rationale for nighttime dosing: The largest natural GH pulse occurs 30-60 minutes after sleep onset. Aligning sermorelin injection with this window amplifies rather than overrides the natural pulse.
- Cycle: Typically used continuously with monitoring, unlike some peptides with mandatory cycles
Combination with Ipamorelin
Sermorelin (GHRH pathway) and ipamorelin (ghrelin/GHRP pathway) work through completely independent receptor systems. Combining them produces a synergistic GH pulse that is substantially larger than either alone — sometimes described as a 3-5× amplification vs each compound solo. This combination is one of the most commonly used GH optimization protocols in longevity medicine.
The combination is typically injected together in a single syringe before sleep. IGF-1 response is stronger and more reliable with the combination than with either agent alone.
What to Expect: Timeline
- Weeks 1-4: Most users report improved sleep quality — deeper sleep, more vivid dreams, feeling more rested. This reflects the GH pulse during sleep.
- Months 1-3: Gradual body composition changes become apparent — subtle reduction in visceral fat, some increase in lean mass if training is consistent.
- Months 3-6: More pronounced body composition changes, potential improvements in skin quality, energy levels, and recovery from exercise.
- IGF-1 response: Should be measurable at 8-12 weeks if the protocol is being followed correctly.
- IGF-1 — baseline, then every 3 months
- Fasting glucose — GH can affect insulin sensitivity
- HbA1c annually — especially important in those with metabolic risk
- Subjective sleep quality — weekly tracking
- Body composition — DEXA or consistent waist circumference measurement
Sermorelin vs CJC-1295 vs Exogenous HGH Comparison
| Property | Sermorelin | CJC-1295 (no-DAC) | CJC-1295 (DAC) | Exogenous HGH |
|---|---|---|---|---|
| Mechanism | GHRH receptor agonist | GHRH receptor agonist (modified) | Long-acting GHRH analogue | Direct GH replacement |
| Half-life | ~10-20 min | ~30 min | 6-8 days | 15-30 min (sc) |
| GH release pattern | Pulsatile | Pulsatile | Sustained elevation | Sustained non-physiological |
| Pituitary feedback | Preserved | Preserved | Partially blunted | Bypassed |
| IGF-1 effect | Moderate increase | Moderate-strong increase | Sustained elevation | Strong elevation |
| Regulatory status | Former FDA approval (withdrawn for commercial reasons) | Research peptide | Research peptide | Prescription in India/US |
| Cost (relative) | Low-medium | Low-medium | Low | Very high |
Frequently Asked Questions
Sermorelin stimulates your pituitary to release its own growth hormone using the body's natural GHRH receptor pathway. Exogenous HGH bypasses this system entirely. The key difference is physiological regulation — sermorelin maintains feedback loops that prevent excess GH/IGF-1, while exogenous HGH can create supraphysiological levels with greater risk of side effects including insulin resistance and acromegaly features with long-term use.
By increasing GH pulsatility and IGF-1, sermorelin promotes fat mobilization (particularly visceral fat), increases muscle protein synthesis, and improves nitrogen retention. Body composition improvements typically become apparent after 3-6 months of consistent use, with sleep quality improvement being the earlier observable effect. Training and nutrition quality strongly influence the magnitude of response.
IGF-1 is the primary biomarker. Measure baseline before starting and retest at 8-12 weeks. Target the upper third of your age-adjusted reference range. If IGF-1 hasn't risen meaningfully, consider dose increase, timing optimization, or adding ipamorelin. Track sleep quality, body composition changes, and fasting glucose in parallel.
They work through different pathways and are best used together. Sermorelin alone produces a moderate GH pulse. Ipamorelin alone produces a cleaner GH pulse than older GHRPs. Combined, they produce a synergistic effect significantly larger than either alone. If forced to choose solo, most practitioners prefer the combination, but ipamorelin is often used alone for its favorable side effect profile.
Sermorelin is not approved in India but is available through research chemical suppliers domestically and internationally. Its former FDA approval status gives it a better established safety profile than most research peptides. Physician supervision for IGF-1 monitoring and dose optimization is strongly recommended.